Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05740956
Other study ID # HS-10502-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 9, 2023
Est. completion date October 1, 2026

Study information

Verified date February 2023
Source Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact Lingying Wu, Medical PhD
Phone 13910865483
Email wulingying@csco.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 318
Est. completion date October 1, 2026
Est. primary completion date April 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Males or females aged 18 - 75 years (inclusive). 2. Having at least one target lesion per the RECIST v1.1. 3. For the phase Ia Cohort A: advanced solid tumor carrying HRR gene mutation with failure or intolerance or not available to the currently available Standard of care (SoC). 4. For the phase Ib study: Cohort B: patients with HRD positive recurrent ovarian cancer with failure or intolerance or not available to SoC Cohort C: patients with HRR gene mutation advanced Human epidermal growth factor receptor 2 (HER2)-negative breast cancer with failure or intolerance or not available to SoC Cohort D: patients with HRR gene mutation advanced pancreatic cancer with failure or intolerance or not available to SoC Cohort E: patients with HRR gene mutation mCRPC with failure or intolerance or not available to SoC Cohort F: patients with HRR gene mutation colorectal cancer with failure or intolerance or not available to SoC Cohort G: patients with other HRR gene mutation or HRD positive advanced solid tumors with failure or intolerance or not available to SoC 5. Eastern cooperative oncology group (ECOG) performance status was 0-1. 6. Minimum life expectancy > 12 weeks. 7. Females should be using adequate contraceptive measures and should not be breastfeeding Males should be using adequate contraceptive measures. 8. Have signed Informed Consent Form. Exclusion Criteria: 1. Received or are receiving the following treatments: 1. Previous or current treatment with two or more Poly(ADP-ribose) polymerase (PARP) inhibitors. 2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment. 3. Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment; Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment. 4. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment. 5. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion. 6. Major surgery within 4 weeks prior to the first dose of study treatment. 2. Presence of Grade = 2 toxicities due to prior anti-tumor therapy. 3. History of other primary malignancies. 4. Known and untreated, or active central nervous system metastases. 5. Inadequate bone marrow reserve or hepatic and renal functions. 6. Myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), or with features suggestive of MDS or AML. 7. Severe, uncontrolled or active cardiovascular disorders. 8. Diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to the first dose of study treatment; glycosylated hemoglobin = 7.5%. 9. Serious or poorly controlled hypertension. 10. Any life-threatening hemorrhagic event or events requiring blood transfusion within 120 days prior to the first dose of study treatment. Clinically significant hemorrhagic symptoms or obvious hemorrhagic tendency. 11. Serious infection within 4 weeks prior to the first dose of study treatment, or presence of uncontrollable active infection in the screening period. 12. Having serious neurological or mental disorders. 13. A history of hypersensitivity to any of the active or inactive ingredients of HS-10502 or drugs with a similar chemical structure to HS-10502 or in the same class as HS-10502. 14. Patients who may have poor compliance with the procedures and requirements of the study, as judged by the investigator. 15. Patients with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.

Study Design


Intervention

Drug:
HS-10502
HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.

Locations

Country Name City State
China Cancer Hospital Chinese Acedemy of Medical Sciences Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of HS-10502(Stage 1) MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a Dose-limiting toxicity (DLT) Cycle 1 (28 days)
Primary Maximum applicable dose (MAD) of HS-10502(Stage 1) MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the pharmacokinetics-pharmacodynamics (PK-PD) model, it suggested that the optimal target concentration of safety and efficacy has been explored Cycle 1 (28 days)
Primary Efficacy of HS-10502: Objective response rate (ORR)(Stage 2) ORR is defined as the proportion of participants with Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only) From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Incidence and severity of treatment-emergent adverse events Assessed by number and severity of adverse events as evaluated according to NCI CTCAE v5.0. From Cycle 1 Day 1 (C1D1) until 28 days after the final dose. A cycle is 28 days
Secondary [Stage 1 and Stage 2] PK parameters: The maximum observed concentration (Cmax) of HS-10502 Maximum plasma drug concentration of HS-10502 Cycle 1 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: time to Cmax (Tmax) of HS-10502 Time of maximum observed concentration of HS-10502 Cycle 1 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: area under the concentration-time curve from time 0 to time t of last measurable concentration (AUC0-t) of HS-10502 Area under the curve from the time of dosing to the time of the last measurable (positive) concentration Cycle 1 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: Maximum plasma concentration at steady state (Css, max) of HS-10502 Maximum plasma drug concentration at steady state of HS-10502. Cycle 2 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: time to Css, max (Tss, max) of HS-10502 Time of maximum observed concentration at steady state of HS-10502 Cycle 2 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: Minimum plasma concentration at steady state (Css, min) of HS-10502 Minimum plasma drug concentration at steady state of HS-10502 Cycle 2 Day 1 (each cycle is 28 days)
Secondary [Stage 1 and Stage 2] PK parameters: Area under the plasma concentration-time curve over a dosing interval at steady state (AUCss) of HS-10502 The partial area from dosing time to dosing time plus dosing interval of HS-10502 Cycle 2 Day 1 (each cycle is 28 days)
Secondary Efficacy of HS-10502: ORR Proportion of participants with BOR of confirmed CR or confirmed Partial Response (PR) per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and The prostate cancer working group 3 criteria (PCWG3) (for prostate cancer only) From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: disease control rate (DCR) P Percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks) per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only) From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary Title: [Stage 1 and Stage 2] Efficacy of HS-10502: duration of response (DoR) DoR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only). The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is the date of the first documented progression or death due to underlying cancer. From the date of CR, PR until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: progression free survival (PFS) (applicable for all solid tumors except prostate cancer) Time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1. From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years.
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: radiographic progression free survival (rPFS) (for prostate cancer only) Time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. rPFS will be assessed per RECIST v1.1 (soft tissue) and PCWG3 (bone). From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: ORR evaluated by RECIST v1.1 and Gynecologic Cancer Intergroup (GCIG) CA-125 (for ovarian cancer only) Proportion of participants with BOR of confirmed CR or confirmed PR per both RECIST v1.1 and GCIG CA-125 criteria. From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 2] Efficacy of HS-10502: overall survival (OS) Time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 4 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: Proportion of subjects with Carbohydrate antigen (CA)-125 decreased by = 50% from baseline (for ovarian cancer only) The percentage of subjects (ovarian cancer only) with a reduction of at least 50% from baseline in CA-125 levels. From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: = 50% PSA decrease (PSA50) response rate (for prostate cancer only) Proportion of subjects with a Prostate-specific antigen (PSA) nadir of = 50% of baseline PSA level confirmed by serial PSA assessments (at least 3 weeks apart) after the start of the study. From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Secondary [Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only) Time from the first dose to PSA progression based on PCWG3 criteria. From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A